title: Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.
abstract: Chemotherapy for non-Hodgkin's lymphoma (NHL) patients with chronic hepatitis B virus (HBV) infection may be accompanied by severe hepatitis. Of 86 consecutive NHL patients, 11 (12.8%) exhibited a positive serum HBsAg. Six of these patients (54.5%) developed acute exacerbation of chronic HBV infection following chemotherapy and received lamivudine. Five of the six patients demonstrated a clinical improvement, one patient died from fulminant hepatic failure owing to delayed lamivudine therapy and poor compliance. These data suggest that HBsAg screening is necessary before commencing chemotherapy for NHL patients in a hyperendemic area and that lamivudine is effective in treating hepatitis B reactivation during chemotherapy.
authors.affiliation: Liver Unit, Kaohsiung Medical Centre, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
authors.forename: Chun-Ann
authors.initials: CA
authors.lastname: Liao
authors.forename: Chuan-Mo
authors.initials: CM
authors.lastname: Lee
authors.forename: Hong-Cheng
authors.initials: HC
authors.lastname: Wu
authors.forename: Ming-Chung
authors.initials: MC
authors.lastname: Wang
authors.forename: Sheng-Nan
authors.initials: SN
authors.lastname: Lu
authors.forename: Hock-Liew
authors.initials: HL
authors.lastname: Eng
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000254:growth & development; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine